Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Gaffen SL – Interleukin (IL)–17 (also known as IL–17A), the signature cytokine of the newly described T helper 17 (Th17) cell population, has been implicated in the pathogenesis of numerous autoimmune diseases including rheumatoid arthritis. This article discusses the history of the discovery of Th17 cells, the potential mechanisms of action of IL–17 in autoimmunity, and perspectives for IL–17–targeted cytokine therapy.

Related Articles

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09    Relevance Score: 84%

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09    Relevance Score: 84%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09    Relevance Score: 84%

Rheumatoid Arthritis and Tuberculous Arthritis: Differentiating MRI Features
American Journal of Roentgenology, 10/26/09    Relevance Score: 83%

The association between arthritis and psychiatric disorders; results from a longitudinal population-based study
Journal of Psychosomatic Research, 10/12/09    Relevance Score: 83%

Today in Rheumatic/Autoimmune...keeping you current

Update on the genetic risk factors for rheumatoid arthritis
Expert Review of Clinical Immunology, 12/18/09

Non-avian-derived hyaluronan for the treatment of osteoarthritis of the knee
Expert Review of Clinical Immunology, 12/18/09

Anti-TNF-[alpha] therapy with infliximab in spondyloarthritides
Expert Review of Clinical Immunology, 12/17/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address